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Genetic determinants of cognition are poorly characterized and their relationship to 
genes that confer risk for neurodevelopmental disease is unclear. Here, we used a 
systems-level analysis of genome-wide gene expression data to infer gene-regulatory 
networks conserved across species and brain regions. Two of these networks, M1 and 
M3, showed replicable enrichment for common genetic variants underlying healthy 
human cognitive abilities including memory. Using exome sequence data from 6,871 
trios, we find that M3 genes are also enriched for mutations ascertained from patients 
with neurodevelopmental disease generally, and intellectual disability and epileptic 
encephalopathy in particular. M3 consists of 150 genes whose expression is tightly 
developmentally regulated, but which are collectively poorly annotated for known 
functional pathways. These results illustrate how systems-level analyses can reveal 
previously unappreciated relationships between neurodevelopmental disease genes in 
the developed human brain, and provide empirical support for a convergent gene-
regulatory network influencing cognition and neurodevelopmental disease.  
 
Cognition refers to human mental abilities such as memory, attention, processing speed, 
reasoning and executive function. Performance on cognitive tasks varies between individuals 
and is highly heritable1 and polygenic2,3. However, to date, progress in identifying molecular 
genetic contributions to healthy human cognitive abilities has been limited4,5.  
 
A distinction can be made between cognitive domains such as the ability to apply acquired 
knowledge and learned skills (so called crystallized abilities) and fluid cognitive abilities such 
as the capacity to establish new memories, reason in novel situations or perform cognitive 
tasks accurately and quickly6. Notably, within individuals, performance on different measures 
of cognitive ability tend to be positively correlated such that people who do well in one 
domain, such as memory, tend to do well in other domains7. Seemingly disparate domains of 
cognitive ability also show high levels of genetic correlation in twin studies, typically in 
excess of 0.68, and analyses using genome-wide similarity between unrelated individuals 
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(genome-wide complex trait analysis, GCTA) has also demonstrated substantial genetic 
correlation between diverse cognitive and learning abilities9,10. These studies suggest genes 
that influence human cognition may exert pleiotropic effects across diverse cognitive domains, 
such that genes regulating one cognitive ability might influence other cognitive abilities.  
 
Since impairment of cognitive function is a core clinical feature of many neurodevelopmental 
diseases including schizophrenia11, autism12, epilepsy13 and intellectual disability (by 
definition), we sought to investigate gene-regulatory networks for human cognition and to 
determine their relationship to neurodevelopmental disease. An overview of our experimental 
design is provided in Supplementary Fig. 1.  
 
 
RESULTS 
Gene co-expression network analysis 
We hypothesized that unsupervised genome-wide co-expression network analysis starting 
from the human hippocampus may be informative for genes and pathways influencing 
cognition. Specifically, gene co-expression network analysis could prioritize sets of genes 
preferentially enriched for common variants (i.e., SNPs) associated with cognitive abilities 
and so reveal novel genetic pathways influencing variable cognitive performance.  
 
We used as our starting material 122 fresh-frozen whole-hippocampus samples surgically 
resected en bloc from patients with temporal lobe epilepsy (TLE) (Supplementary Table 1). 
We chose surgical hippocampus samples from living patients in order to avoid potential 
unwanted effects on gene expression related to the variable agonal state or time to autopsy 
associated with post-mortem samples. In addition, we used several gene expression datasets 
(detailed below) to assess the reproducibility of the identified gene networks in non-TLE 
hippocampi both across species and across brain regions.  
 
 4 
We first determined gene co-expression networks in the human hippocampus by weighted 
gene co-expression network analysis (WGCNA), which groups sets of covarying genes across 
the sample set into co-expression ‘modules’14. Applied to the full set of 122 samples, 
WGCNA grouped the human hippocampus transcriptome into 24 distinct co-expression 
modules (M1-M24), which varied in size from 29 to 1,148 genes (Fig. 1a, Supplementary 
Table 2).  
 
To identify which of the 24 hippocampus modules from patients with TLE had co-expression 
patterns unrelated to epilepsy, for each module, we compared its co-expression topology in 
patients with TLE with that from hippocampus samples ascertained from persons with no 
history of psychiatric or neurological illness15. This comparative network analysis was 
undertaken using the default network dissimilarity measure in WGCNA based on the 
topological overlap matrix (TOM)14. Empirical P values for the validity (i.e., reproducibility) 
of modules were calculated by comparing the average topological overlap for module genes 
to the average connectivity of 10,000 randomly sampled networks (Methods). After 
Bonferroni adjustment for the number of modules tested we found that 16 of the 24 modules 
were significantly preserved in 63 non-diseased human post-mortem hippocampus samples 
(empirical P≤0.002) (Fig. 1a, Supplementary Table 3), suggesting the co-expression of 
genes in these 16 modules is unrelated to epilepsy. Additionally, preservation of these 16 co-
expression modules in a distinct human hippocampus gene expression dataset provides an 
independent line of evidence to support the validity of these modules.  
 
Since molecular pathways underlying cognitive processes might be evolutionarily 
conserved16,17,18 and indeed the rodent hippocampus has long been the primary model for 
studying molecular processes related to learning and memory19, we next aimed to identify 
which of the human hippocampus co-expression modules are preserved in the healthy mouse 
hippocampus. To this aim, we carried out high-throughput sequencing of mRNA (RNA-seq) 
on snap-frozen hippocampus samples from 100 healthy adult mice and assessed the co-
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expression patterns between the mouse orthologs of human hippocampus module genes 
(Methods). Of the 16 human hippocampus modules preserved between non-diseased post-
mortem hippocampus and surgical hippocampus samples from patients with TLE, four 
modules (M1, M3, M11 and M19) were also significantly preserved in the healthy mouse 
hippocampus (empirical P≤0.002) (Fig. 1a, Supplementary Table 3).  
 
To assess whether the four cross-species conserved hippocampus modules (M1, M3, M11, 
M19) are specific to the hippocampus or more widely expressed and co-expressed across the 
human cortex, we then analyzed genome-wide gene expression data from 102 post-mortem 
human brains from the UK Brain Expression Consortium (UKBEC)20 across the following 
brain regions: cerebellum, temporal cortex, occipital cortex, and frontal cortex. Each brain 
region was treated as an independent dataset and gene expression levels in UKBEC were 
adjusted for age, gender, post-mortem interval, cause of death and brain bank ID. 
Comparative network analysis was undertaken as above, and showed preservation of all four 
hippocampus co-expression modules in multiple other brain regions (Supplementary Table 
4). Therefore, despite the modules being originally re-constructed from hippocampus gene 
expression data, these results suggest the modules are not specific to the hippocampus and so 
might be capturing functions that are more widely distributed in the human cortex.  
 
Analyses of biological terms and canonical pathways enriched among the genes in all 24 
hippocampus modules from TLE patients are shown in Supplementary Table 5. As a general 
observation, the different hippocampal co-expression modules demonstrated notable 
functional specificity. Of the four modules conserved in healthy hippocampi across species 
(M1, M3, M11, M19), only M1 (n=1,148 genes) and M3 (n=150 genes) were enriched for 
functional categories explicitly related to synaptic processes (Fig. 1b). Module M1 was 
highly enriched for Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathways ‘calcium 
signaling’ (Benjamini-Hochberg (BH) corrected P=7.3×10-7, ratio of enrichment (r)=3.0), 
‘axon guidance’ (BH P=9.0×10-5, r=2.5) and ‘long-term potentiation’ (LTP) (BH P=4.0×10-3, 
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r=5.0), and for the gene ontology (GO) terms ‘synapse’ (BH P=6.9×10-15, r=2.5), ‘neuron 
projection’ (BH P =1.4×10-14, r=2.2) and ‘synaptic vesicle’ (BH P=2.9×10-8, r=3.5). Module 
M3 was enriched for genes belonging to ‘postsynaptic density’ (PSD) (BH P=9.0×10-4, r=6.6) 
and ‘Reelin signaling pathway’ (BH P=0.049, r=12.5). We therefore investigated further 
whether M1 and M3 were enriched for genes for post-synaptic complexes using a set of 671 
proteins in human neocortical PSD and 79 proteins related to NMDAR/ARC complexes 
previously implicated in neurodevelopmental disease, memory and intelligence21,17,22,5. We 
found that genes comprising the PSD and NMDAR/ARC complexes were significantly 
overrepresented in M1 (Fisher’s exact test (FET) P=5.4×10-13, Odds Ratio (OR)=2.10, 95% 
confidence interval (95% CI) [1.73-2.55] and P=2.6×10-8, OR=4.25, 95% CI [2.57-6.90], 
respectively) but not in M3 (Fig. 1c). However, manual annotation of gene function for M3 
genes revealed that 58 of the 121 genes with a reported putative function had a biological 
activity potentially related to neurodevelopment (Supplementary Table 6), suggesting M3 is 
also capturing novel connectivity between genes that share related neural functions. Analysis 
of physical interactions between the protein products of genes in M1 and M3 using the InWeb 
database23 found significant enrichment for direct protein-protein interactions (PPI) for M1 
(551 of 1,148 genes, P=0.001) and M3 (17 of 150 genes, P=0.02), providing a further line of 
evidence to support the validity of these two co-expression modules.  
 
In summary, these comparative genome-wide network analyses starting from human surgical 
hippocampus samples identify four modules (M1, M3, M11 and M19) that are cross-species 
conserved and whose constituent genes are widely co-expressed across the human brain. Two of 
these modules (M1 and M3) are highlighted as having potential function related to neural activity.  
 
Integrated cognitive GWAS and gene network analysis  
To determine the relationship between the four cross-species preserved co-expression modules 
(M1, M3, M11 and M19) and human cognitive function we tested each module for an enriched 
genetic association with four cognitive phenotypes (general fluid cognitive ability, processing 
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speed, crystalized cognitive ability and verbal delayed recall) in two independent cohorts of 
cognitively healthy subjects. Our Discovery cohort consisted of genome-wide association 
study (GWAS) data relating to 6,732 (after QC) cognitively healthy subjects participating in 
the “Generation Scotland: Scottish Family Health Study” (GS:SFHS)24. The Replication 
cohort consisted of independent GWAS data relating to 1,003 (after QC) cognitively healthy 
subjects participating in the Lothian Birth Cohort 1936 (LBC1936)25. Mean age at assessment 
was 55 years (standard deviation (SD)=11.35) in GS:SFHS and 69.6 years (SD=0.8) in 
LBC1936. Details describing how the cognitive phenotypes were derived and GWAS analysis 
are provided in Methods.  
 
To test each module’s association to the four cognitive phenotypes we first used VEGAS26 
(versatile gene-based association study) to account for the number of SNPs in each gene and 
the linkage disequilibrium (LD) between those SNPs followed by GWAS-enrichment analysis 
using the Z-score enrichment method27 (Methods). As a negative control, and to assess 
specificity of the GWAS-enrichments, each module was also tested against five large GWAS 
of clinical phenotypes with no known relationship to healthy cognitive performance (waist-
hip ratio, fasting glucose homeostasis, glucose challenge homeostasis, systolic blood pressure 
and diastolic blood pressure (Supplementary Table 7).  
In the larger Discovery cohort (GS:SFHS), we found nominal enrichment of association 
(P<0.05) for M1 with general fluid cognitive ability, processing speed, crystalized cognitive 
ability and verbal delayed recall, and for M3 with general fluid cognitive ability, processing 
speed and verbal delayed recall (Table 1). Neither M1 nor M3 was enriched for association to 
any of the five non-cognitive control phenotypes despite the substantial sample size and 
power of these GWAS studies (Supplementary Table 7). M11 and M19 were not 
significantly (P<0.05) enriched for association with any cognitive phenotype. We adopted a 
false discovery rate (FDR) adjustment based on the number of modules and phenotypes tested 
in the Discovery cohort GS:SFHS, and modules significantly enriched for association at FDR 
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<10% were taken forward for replication in LBC1936. The strongest replicable enrichment of 
association was between M3 and general fluid cognitive ability (GS:SFHS P=0.002, Z-
score=2.95; LBC1936 P=0.004, Z-score=2.66) (Table 1). In addition, we observed replicable 
enrichment of association between M3 and delayed recall (GS:SFHS P=0.038, Z-score=1.77; 
LBC1936 P=0.005, Z-score=2.56). For M1, we observed replicable enrichment of association 
with delayed recall (GS:SFHS P=0.016, Z-score=2.14; LBC1936 P=0.006, Z-score=2.51) and 
crystalized cognitive ability (GS:SFHS P=0.020, Z-score=1.96; LBC1936 P=0.045, Z-
score=1.70).  
These results suggest modules M1 and M3 are enriched for genes related to general cognitive 
ability including memory. We therefore further explored M1 and M3 by investigating their 
expression in different stages of human brain development following the method of Pletikos28 
and by undertaking a detailed analysis of brain region expression of M1 and M3 genes. 
Utilizing data from Kang and colleagues29 consisting of gene expression measurements from 
11 topographically defined cortical areas from 53 human brains spanning 10 weeks post-
conception (PCW) to 82 years of age (Methods), we observed a clear developmental gradient 
of expression of both M1 and M3 beginning in early mid-fetal development (16 ≤ PCW ≤ 19), 
maximal by birth and then persisting through all post-natal periods (Fig. 1d). Consistent with 
the co-expression analyses using UKBEC data (above and Supplementary Table 4), we 
observed that following birth M1 and M3 genes are highly expressed across the human cortex 
with the exception of striatum, mediodorsal nucleus of thalamus and cerebellar cortex. The 
developmentally regulated expression of M1 and M3 genes across diverse brain regions is 
consistent with the genetic evidence (Table 1 and above) suggesting these modules play a 
broader role in human cognitive abilities beyond hippocampal memory.  
 
The tightly regulated developmental trajectory of expression of M1 and M3 led us to explore 
their transcriptional control. Using the WebGestalt toolkit30 to test for enrichment of 
transcription factor binding sites (TFBS) among M1 and M3 genes, we found M1 was highly 
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enriched for NRSF/REST (repressor element 1-silencing transcription factor) targets (BH 
P=0.0006), and this was confirmed using a set of previously published and experimentally 
derived targets of REST31 (enrichment P=0.007). For M3, the maximum TFBS enrichment 
was for SRY (sex determining region Y) transcription factor (BH P=0.01). However, using 
publicly available data on sex-biased gene expression in the brain29 we found no evidence of 
enrichment for male-specific genes in M3 (data not shown). In addition, we found no 
significant enrichment for experimentally derived REST targets in M3 (P=0.67), suggesting 
different processes underlie the transcriptional regulation of M1 and M3 in the brain.  
 
Burden of neurodevelopmental de novo mutations in gene networks  
Extensive epidemiological and genetic evidence suggest that clinically distinct 
neurodevelopmental disorders could be thought of as reflecting different patterns of 
symptoms (or impairments) of a shared neurodevelopmental continuum32. The co-occurrence 
of clinical symptoms and diagnostic overlap between neuropsychiatric disorders has also 
meant that diseases such as epilepsy are increasingly considered within the 
neurodevelopmental spectrum33. Since cognitive impairment is a core component of many 
neurodevelopmental disorders including schizophrenia11, autism12 and epilepsy13, we set out 
to explore the relationship between the four cross-species conserved gene co-expression 
modules (and in particular M1 and M3) and susceptibility to neurodevelopmental disease.  
 
To this aim, we first assessed if any of the modules were enriched for genes intolerant to 
functional mutation using the Residual Variation Intolerance Score (RVIS)34; genes 
considered to be intolerant to mutation according to their RVIS are more likely to be 
associated with developmental disease when mutated34,35. Using the individual RVIS for each 
gene in a module we calculated a module-level RVIS and compared the distribution of RVIS 
scores for each module to the distribution of intolerance scores from all hippocampus-
expressed protein-coding genes outside of that module (Methods). Of the four cross-species 
conserved modules, three (M1, M3 and M11) were significantly enriched for intolerant genes 
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(Supplementary Table 8), meaning that these modules contain an excess of genes intolerant 
to functional genetic variation relative to the genome-wide expectation. Given their cross-
species preservation of co-expression, this finding suggests selective constraints on these 
modules in terms of both their coding sequence and transcriptional regulation.  
 
We then investigated the relationship between the four cross-species conserved modules and 
neurodevelopmental disease by testing each module for enrichment of validated non-
polymorphic de novo single nucleotide variant mutations (DNMs) identified in 
neurodevelopmental whole-exome sequencing (WES) studies that shared similar sequencing 
technologies, coverage criteria and variant calling methodology (Methods). Collectively, the 
neurodevelopmental disease cohort consisted of 5,738 non-overlapping published parent-
offspring trios across four disease phenotypes; autism spectrum disorder (ASD, n=4,186), 
schizophrenia (SCZ, n=1,004), intellectual disability (ID, n=192) and epileptic 
encephalopathy (EE, n=356) (see Methods  for cohort references). Additionally, we 
considered DNMs from an independent cohort of 1,133 trios with severe, previously 
undiagnosed developmental disease from the Deciphering Developmental Disorders (DDD) 
study36,37. For controls, we used 1,891 non-neurological control samples from seven published 
studies38,39,40,41,42,43,44. 
 
Each module’s genetic relationship to disease was then tested using two statistical approaches. 
First, we compared rates of DNMs in each module compared to random expectation based on 
the collective consensus coding sequence (CCDS) of module genes. The expected number of 
DNMs for each gene set (i.e., module) was calculated based on the length of CCDS sequence 
of genes in the set and the overall frequency of DNM in all CCDS genes. Then to estimate the 
enrichment we used the ratio between the observed number of DNMs in the gene set and the 
expected number based on this length model using binomial exact test (BET, two-tail).  
Secondly, to accommodate for sequence context factors such as the inherent mutability of 
genes in a module, we adopted a FET (two-tail) to empirically compare the rates of DNMs 
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overlapping the CCDS real estate of a module in case- and control cohorts. This approach is 
also able to identify modules comprised of genes that are preferentially depleted of DNMs in 
healthy controls. For each module, we report DNM enrichments by both approaches and by 
considering three main classes of mutation: (a) predicted deleterious DNM (pdDNM) 
consisting of loss-of-function (nonsense and splice-site mutations) and predicted functional 
missense mutations, (b) non-synonymous DNM (nsDNM) consisting of all missense, 
nonsense and splice-site mutations and (c) synonymous DNM (as a negative control). For 
completeness, we also report enrichments considering only loss-of-function (i.e., nonsense 
and splice-site) mutations, although we expect limited power to detect significant enrichments 
given that single nucleotide DNMs in this class were relatively uncommon in the 
neurodevelopmental disease cohorts used here. Finally, to assess specificity of the module-
level enrichment results, for each class of DNM detailed above we calculated an enrichment 
of DNM among all genes significantly expressed in the human hippocampus (hereon termed 
“Background” genes), taking the conservative route of including in this set of genes all the 
genes contributing to the individual co-expression modules.  
 
We observed that module M3 was strongly and specifically enriched for genes that when 
mutated are associated with intellectual disability and epileptic encephalopathy, and that this 
enrichment holds true for both pdDNM (ID BET P=6.6x10-5, FET P=3.1x10-4, OR=10.29, 
95% CI [2.56-48.91]; EE BET P=1.9x10-6 , FET P=7.1x10-5 , OR=9.1, 95% CI [2.64-39.47]) 
and all nsDNM (ID BET P=3.3x10-5, FET P=1.4x10-5, OR=11.22, 95% CI [3.51-38.84]; EE 
BET P=1.3x10-5 , FET P=9.1x10-6, OR=8.52, 95% CI [2.99-27.56]) (see Fig. 2 and 
Supplementary Table 9). These enrichments remained significant after adjustment for the 
number of modules and phenotypes tested. M1 was not significantly enriched for any 
neurodevelopmental disease above the Background (Fig. 2). There was no enrichment in M3 
of disease-ascertained synonymous DNM for either ID (BET P=0.251, FET P=0.239) or EE 
(BET P=0.576, FET P=0.522), or any other neurodevelopmental phenotype (Supplementary 
Table 9).  
 12 
 
For ASD and SCZ, there was a trend towards enrichment of disease-ascertained DNM in M3 
but estimates of the 95% confidence intervals of the odds ratio overlapped with those from 
Background genes (Fig. 2). However, when combining all 5,738 trios with 
neurodevelopmental disease (i.e., ID + EE + ASD + SCZ) we observed significant enrichment 
of nsDNM in M3 above Background (BET P=3.54x10-6 , FET P=9.0x10-4, OR=3.54, 95% CI 
[1.51-9.74]) (Fig. 2), suggesting M3 is enriched for genes impacted by DNM associated with 
neurodevelopmental disease broadly and with ID and EE in particular. Consistent with this 
interpretation, M3 was also significantly enriched for nsDNM ascertained from unselected 
developmental phenotypes from the independent DDD study36,37 (BET P=2.2x10-3, FET 
P=1.0x10-3, OR=4.08, 95% CI [1.60-12.35]) (Fig. 2, Supplementary Table 9).  
 
In total, almost a third of genes in M3 (43 out of 150) were impacted by one or more nsDNM 
across the five disease cohorts considered here (ID, EE, ASD, SCZ, DDD). These 43 genes 
and their corresponding mutation (with functional consequence) and disease phenotype are 
shown in Table 2 and Fig. 3. Among the 43 genes in M3 impacted by nsDNM several genes 
including SCN2A, GABRB3, GNAO1, TCF4, GRIN2A and UPF3A are known 
neurodevelopmental disease genes. Thus starting from an unsupervised gene network 
perspective, M3 reveals previously unappreciated co-expression between genes for 
heterogeneous neurodevelopmental disorders in the developed human brain.  
 
The finding that M3 is highly enriched for genes that confer risk for neurodevelopmental 
disease when mutated led us to explore the relationship between M3 and neuropsychiatric 
disease using GWAS data relating to the Psychiatric Genomics Consortium (PGC) traits 
attention deficit-hyperactivity disorder (ADHD), bipolar disorder (BP), major depressive 
disorder (MDD) and SCZ45, as well as GWAS data relating to common forms of epilepsy 
from the International League Against Epilepsy (ILAE) Consortium on Complex Epilepsies46 
and those from a risk and age of onset of Alzheimer’s disease (AD)47. M3’s enrichment of 
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association to each phenotype was tested as previously described (Methods). After 
Bonferroni correction for multiple testing, the only significant association was between M3 
and SCZ (enrichment P=0.003, Z-score=2.76) (Supplementary Table 10). The 
corresponding enrichment statistics for SCZ trio-ascertained DNM were as follows: pdDNM 
BET P=2.14x10-3, FET P=0.013, OR=4.52, 95% CI [1.25-20.27] and nsDNM BET P=0.08, 
FET P=0.029, OR=3.35, 95% CI [1.1-11.28], suggesting M3 may be enriched for genes in 
which both common and rare variants contribute risk for schizophrenia.  
 
DISCUSSION 
In these studies, we have used a step-wise procedure to prioritize gene networks whose gene 
co-expression relationships were significantly reproducible across brain regions and species 
in order to facilitate the identification of functionally conserved and replicable networks. We 
have demonstrated replicable association between two of these co-expression networks (i.e., 
M1 and M3) and healthy human cognitive abilities. Since M1 is functionally enriched for 
genes involved in synaptic processes, these findings provide systems-level evidence for a 
relationship between LTP and post-synaptic processes and human cognition, as previously 
suggested by an analysis of known post-synaptic signaling complexes5. In contrast to the 
functional specialization of M1, M3 is relatively poorly annotated for known functional 
categories or canonical pathways, and reveals previously unappreciated co-expression 
relationships between genes influencing cognitive abilities. The finding that M1 and M3 
influence cognitive abilities generally (as opposed to influencing specific cognitive domains 
such as memory) is in agreement with the evidence from twins and GCTA analysis 
demonstrating high genetic correlation between diverse cognitive and learning abilities9,10,48. 
The widespread expression and co-expression of M1 and M3 genes across the human cortex, 
and their tight developmental regulation, is also consistent with these modules playing a role 
across cognitive domains.  
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By analyzing de novo mutations reported in whole-exome sequencing studies of 
neurodevelopmental disease parent-offspring trio cohorts, we found that rare genetic risk 
variants for neurodevelopmental disease also converge on module M3. In total, almost a third 
of genes in M3 were impacted by one or more non-synonymous DNM ascertained from 
neurodevelopmental disease cases. Among the individual genes in M3 mutated in two or 
more cases, most were associated with more than one neurodevelopmental phenotype (Table 
2). These results reveal a convergence of genetic risk variants contributing toward healthy 
human cognitive abilities and neurodevelopmental disease on a shared set of genes under tight 
developmental regulation and widely co-expressed in the human cortex. Nonspecific (or 
pleotropic) effects of pathogenic mutations have recently emerged as a key theme among 
neurodevelopmental disease genes35. Here we provide empirical evidence to suggest this 
pleiotropy also extends to healthy cognitive function, although the underlying mechanisms for 
mutational non-specificity remain unknown.  
One observation from our study is the extent to which the expression of M1 and M3 genes is 
temporally specified. Following birth, the expression of M1 and M3 genes appeared 
remarkably stable over time, consistent with an enduring role for these genes in cognitive 
function throughout life. This is in keeping with the finding of the modules’ association with 
cognition in two independent cohorts that differ in their age at assessment (Table 1). Whilst a 
number of studies have suggested that sequence variation in genes that are developmentally 
regulated can be related to susceptibility to neurodevelopmental disease43,42, here we have 
shown that genes under tight developmental regulation and later co-expressed in the 
developed human brain are also related to this class of disorder, as well as healthy cognitive 
processes. These observations provide a starting point for the identification of gene-regulatory 
factors influencing cognition and neurodevelopmental disease.  
Our analyses integrating DNMs with gene regulatory networks revealed that M3 was 
associated most strongly with intellectual disability and epileptic encephalopathy and to a 
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lesser extent with neurodevelopmental disease in general. This is consistent with the 
hypothesis that genetic variation affecting quantitative variation in cognitive abilities overlaps 
with that underlying related monogenic phenotypes. However, when considering common 
risk variants (i.e., SNPs) for neuropsychiatric disease, we observed an association between 
M3 and schizophrenia but not with common forms of epilepsy. Potential explanations for the 
lack of GWAS enrichment of association between M3 and common epilepsy include different 
gene contributions to severe childhood epileptic encephalopathy arising from rare de novo 
mutations compared to the (mostly) adult epilepsies considered in the ILAE study46, and/or 
insufficient power to detect common variant associations using the ILAE GWAS (which 
although consisting of only 8,696 epilepsy cases and 26,157 controls is the largest epilepsy 
GWAS yet undertaken). Further studies will be required to clarify the specific contribution of 
M3 genes to disease risk across the allelic spectrum, and to elucidate the role of both rare and 
common sequence variants in the complex inheritance of childhood and adult epilepsy.  
 
In conclusion, starting from an unsupervised analysis of gene expression variation in the 
hippocampus and across the brain, we report two cross-species conserved gene co-expression 
networks (M1 and M3) associated with healthy human cognitive abilities and we identify one 
of these (M3) as a convergent gene network for both cognition and neurodevelopmental 
disease. Our experimental framework, which integrates gene network analysis with genetic 
susceptibility data, can be applied generally to any human behavioral or cognitive phenotype 
for which relevant genetic data (GWAS, WES, etc.) are available. We therefore make all our 
human hippocampal gene network and data accessible by means of an integrated web tool 
(Neurodevelopmental disease Brain Integrated Gene Networks, available at 
www.nbign.co.uk). This framework and underlying data may help to tackle the fundamental 
challenge of understanding how genetic risk variants for neurodevelopmental disease and 
related cognitive phenotypes exert their effects in the developed human brain.  
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FIGURE LEGENDS 
Figure 1. Gene co-expression network analysis. (a) Dendrogram showing clustering of co-
expressed genes (modules) based on human surgical hippocampus samples. Top color bar 
(line 1): the 24 modules (M1-M24) generated by unsupervised hierarchical clustering of the 
surgical hippocampal transcriptome; second color bar (line 2): the 16 (of 24) modules whose 
gene co-expression relationships are significantly preserved in non-diseased post-mortem 
human hippocampus; third color bar (line 3): the 5 (of 24) human surgical hippocampus 
modules whose gene co-expression relationships are preserved in the healthy mouse 
hippocampus; bottom color bar: the 4 co-expression modules conserved across all three 
expression datasets (1–3). (b) KEGG and Pathway Commons (Pathways) and Gene Ontology 
(GO) enrichments for M1 (blue) and M3 (black). BP, biological process; MF, molecular 
function; CC, cellular component. For each functional category the ratio of enrichment is 
reported on top of each bar. (c) Enrichment of proteins comprising the postsynaptic density 
(PSD) and N-methyl-D-aspartate (NMDA) receptor/activity-regulated cytoskeleton (ARC) 
complexes in M1 (blue) and M3 (black). ORs of enrichment are reported on top of each bar. 
(d) Heatmap of gradient of expression of modules M1 and M3 spanning fetal development to 
late adulthood and in topographically distinct cortical regions. A1C: auditory cortex; AMY: 
amygdala; CBC: cerebellar cortex; DFC: dorsolateral prefrontal cortex; HIP: hippocampus; 
IPC: posterior inferior parietal cortex; ITC: inferior temporal cortex; M1C: primary motor 
cortex; MD: mediodorsal nucleus of thalamus; MFC: medial pre-frontal cortex; OFC: orbital 
prefrontal cortex; S1C: primary somatosensory cortex; STC: superior temporal cortex; STR: 
striatum; V1C: primary visual cortex; VFC: ventrolateral prefrontal cortex.  
 
Figure 2. Enrichment of non-synonymous single nucleotide de novo mutations (nsDNM) 
from patients with neurodevelopmental disease. Statistical significance of 
overrepresentation of nsDNM in cases compared to controls is reported using Fisher’s exact 
test for epileptic encephalopathy (EE – 356 trios), autism spectrum disorders (ASD – 4,186 
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trios), intellectual disability (ID – 192 trios), schizophrenia (SCZ – 1,004 trios) and across all 
four neurodevelopmental disorders consisting of EE, ID, ASD and SCZ (Combined – 5,738 
trios). The nsDNM of the Deciphering Developmental Disorders (DDD) study (1,133 trios) 
were not combined with the other neurodevelopmental disorders as some of the patients of the 
DDD study had congenital abnormalities without neuropsychiatric features. P value, Odds 
ratio (OR) and 95% confidence intervals (CI) are reported for M1, M3 and all genes 
expressed in the human surgical hippocampus samples (Background). In the forest plot, the 
magnitude of the ORs are represented by the size of the squares and the 95% CI are by 
horizontal lines. Blue = Modules; Red = Background.  
 
Figure 3. Graphical representation of the M3 co-expression network and its relationship 
to neurodevelopmental disease. Genes in M3 impacted by single nucleotide variant non-
synonymous de novo mutations (nsDNM) from neurodevelopmental disease cases are drawn 
separately in a circle (on the right). The size of each node is proportional to the number of 
nsDNM for that gene across the full cohort of 6,871 parent-offspring trios (see Methods). 
Individual nsDNM, their predicted affect and corresponding neurodevelopmental disease 
phenotypes are detailed in Table 2.  
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Table 1: Module enrichment for genetic association with cognitive abilities  
 
   
Discovery (GS:SFHS) 
n=6,732 subjects¶ 
  
Replication (LBC1936) 
n=1,003 subjects¶ 
Module Phenotype Genes* Z-score P-value** (FDR)   Genes* Z-score P-value** 
M1 
General f luid cognitive ability 983 2.33 0.010 (5.3%)   1051 0.73 0.230 
Processing speed 983 1.79 0.040 (8.9%)   1051 0.51 0.300 
Crystalized cognitive ability 983 1.96 0.020 (6.4%)   1051 1.70 0.045 
Delayed recall 1051 2.14 0.016 (6.4%)   1046 2.51 0.006 
M3 
General f luid cognitive ability 135 2.95 0.002 (2.4%)   142 2.66 0.004 
Processing speed 135 2.80 0.003 (2.4%)   142 1.02 0.150 
Crystalized cognitive ability 135 1.60 0.050 (8.9%)   142 -0.10 0.540 
Delayed recall 142 1.77 0.038 (8.9%)   139 2.56 0.005 
M11 
General f luid cognitive ability 121 0.27 0.390 (52%)        
Processing speed 121 -0.63 0.740 (78%)        
Crystalized cognitive ability 121 1.62 0.050 (8.9%)   133 1.09 0.140 
Delayed recall 133 0.04 0.480 (59%)        
M19 
General f luid cognitive ability 466 1.28 0.100 (16%)        
Processing speed 466 -1.29 0.900 (90%)        
Crystalized cognitive ability 466 -0.27 0.610 (69%)        
Delayed recall 504 0.42 0.340 (49%)        
 
Discovery cohort, Generation Scotland: Scottish Family Health Study (GS:SFHS); Replication cohort, Lothian Birth Cohort 1936 (LBC1936); *Genes in the module with ≥1 
genotyped SNP within the transcription start and end positions of the gene (NCBI36, hg18); **P-value for enrichment of association determined by 100,000 bootstrap 
samples; Bold, enrichment of association P<0.05; False discovery rate (FDR) was calculated to account for the number of modules and cognitive domains tested (16 tests); 
Modules with FDR<10% in the Discovery cohort were taken forward for replication in LBC1936. ¶Total number of participants after genotype QC.  
 25 
Table 2: Genes in M3 impacted by neurodevelopmental-ascertained non-synonymous de 
novo mutation.  
Gene 
symbol 
Total 
nsDNM 
Single nucleotide variant 
and predicted effect 
Sift 
Score 
Polyphen 
Score Neurodevelopmental disease cohort 
SCN2A 20 
2:166,245,137 A>T SV -- -- ASD 
    
2:166,201,379 C>A SG -- -- ASD     
2:166,210,819 G>T SG -- -- ASD 
    
2:166,152,367 G>A MS 0.11 0.025 ASD     
2:166,152,578 A>G MS 0 0.999 ASD 
    
2:166,170,231 G>A MS 0 0.999 ASD     
2:166,201,312 G>A MS 0 0.999 ASD     
2:166,231,378 T>C MS 0 1 ASD 
    
2:166,201,311 C>T MS 0 0.999 ASD     
2:166,234,111 C>T MS 0 0.996 ASD 
    
2:166,234,116 A>G MS 0 0.999  EE    
2:166,198,975 G>A MS 0 0.838 
 
EE 
   
2:166,201,311 C>T MS 0 0.999   ID   
2:166,231,415 G>A SG -- -- 
  
ID 
  
2:166,187,838 A>G SV -- --    SCZ  
2:166,153,563 C>T SG -- -- 
    
DDD 
2:166,165,305 G>A SV -- --     DDD 
2:166,245,954 G>A MS 0 0.997 
    
DDD 
2:166,243,484 T>A MS 0 0.972     DDD 
2:166,210,714 T>C MS 0 0.719 
    
DDD 
GABRB3 7 
15:27,017,557 C>T MS 0.04 0.444 ASD     
15:26,828,534 C>T MS 0 0.584 ASD     
15:26,866,594 T>C MS 0.15 0.999 
 
EE 
   
15:26,806,254 T>C MS 0 1  EE    
15:26,866,564 C>T MS 0 0.994 
 
EE 
   
15:26,828,484 T>C MS 0 0.967  EE    
15:26,806,242 A>G MS 0 0.999 
    
DDD 
RYR2 7 
1:237,870,440 C>A MS 0.23 0.034 ASD     
1:237,666,734 C>T MS 0.02 0.947 ASD 
    
1:237,868,631 C>T SG -- --  EE    
1:237,995,907 G>A MS 0 0.998 
  
ID 
  
1:237,982,492 G>T MS 0 0.998     DDD 
1:237,982,471 A>G MS 0 0.658 
    
DDD 
1:237,693,752 G>A MS 0.08 0.36     DDD 
GNAO1 6 
16:56,388,838 G>A MS 0 0.316 ASD     
16:56,385,380 A>C MS 0 0.999 
 
EE 
   
16:56,385,396 T>C MS 0 0.996  EE    
16:56,370,728 G>A MS 0.02 0.964 
   
SCZ 
 
16:56,370,674 C>T MS 0 1     DDD 
16:56,309,901 T>G MS 0 0.799 
    
DDD 
TCF4 5 
18:52,921,925 G>A SG -- --   ID   
18:52,896,230 C>T MS 0 1 
  
ID 
  
18:53,070,725 G>A MS 0 0.942   ID   
18:52,899,819 G>A SG -- -- 
    
DDD 
18:52,895,593 C>T SV -- --     DDD 
GRIN2A 3 
16:9,928,084 G>C MS 0 0.921 
  
ID 
  
16:9,923,342 G>C MS 0.01 0.999   ID   
16:9,857,517 A>G MS 0.01 0.816 
   
SCZ 
 
TCF20 2 
22:42,564,699 G>A MS 1 0   ID   
22:42,575,645 G>A SG -- --     DDD 
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PPP6R2 2 
22:50,857,408 C>T MS 0.01 0.862 ASD     
22:50,857,843 T>C MS 0.01 0.898  EE    
NUAK1 2 
12:106,461,269 G>A SG -- -- ASD 
    
12:106,460,608 G>A MS 0.02 0.997 ASD     
MYCBP2 2 
13:77,700,568 A>G MS 0.54 0.039 ASD 
    
13:77,657,240 G>A MS 0.14 0     DDD 
KCNB1 2 
20:47,990,976 G>A MS 0 1 
 
EE 
   
20:47,990,924 T>G MS 0 1     DDD 
GNB5 2 
15:52,427,874 T>C MS 0 1 ASD 
    
15:52,416,801 T>C MS 0.38 0.68    SCZ  
DLG2 2 
11:83,497,765 G>C MS 0 0.786 ASD 
    
11:83,194,295 C>T SV -- --    SCZ  
BRSK2 1 11:1,471,005 G>C SV -- -- ASD 
    
CAMK1D 1 10:12,595,343 C>A MS 0.06 0.003 ASD     
CERS6 1 2:169,417,831 A>G MS 0.11 0.229 ASD 
    
CNST 1 1:246,754,937 G>A MS 0.07 0.09 ASD     
DENND5B 1 12:31,613,279 G>C MS 0.08 0.305 ASD     
DUSP3 1 17:41,847,180 G>A MS 0 0.921 ASD 
    
GLTSCR1L 1 6:42,796,946 C>G MS 0 1 ASD     
GRIA2 1 4:158,254,055 C>T SG -- -- ASD 
    
GSK3B 1 3:119,582,433 G>T MS 0.01 0.521 ASD     
HNRNPR 1 1:23,637,156 G>A MS 0 0 ASD 
    
KLHL28 1 14:45,400,640 A>G MS 0.99 0.324 ASD     
MAP1B 1 5:71,491,094 G>T MS 0.33 0 ASD 
    
MCM4 1 8:48,883,381 G>C MS 0.04 0.363 ASD     
NT5C3A 1 7:33,055,445 A>G MS 0.14 0.546 ASD 
    
PAPD5 1 16:50,263,085 G>A MS 0.09 0.027 ASD     
PIAS1 1 15:68,378,807 G>A MS 0.16 1 ASD 
    
PUM1 1 1:31,437,728 G>A MS 0 0.999 ASD     
UPF3A 1 13:115,057,116 G>A MS 0 1 ASD     
GABRB1 1 4:47,405,630 T>C MS 0 0.998 
 
EE 
   
SGK223 1 8:8,234,597 C>A MS 0.01 0.36  EE    
HIVEP3 1 1:42,047,669 G>A SG -- -- 
   
SCZ 
 
PCDHAC2 1 5:140,346,499 G>T SG -- --    SCZ  
SSBP3 1 1:54,870,560 G>A SG -- -- 
   
SCZ 
 
TAF13 1 1:109,607,282 G>A SG -- --    SCZ  
TNRC6C 1 17:76,083,048 C>G MS 0.01 0.808 
   
SCZ 
 
PHACTR1 1 6:12,933,928 G>A MS 0.02 0     DDD 
PLEKHB2 1 2:131,884,360 G>A SV -- -- 
    
DDD 
ROBO2 1 3:77,637,907 C>T MS 0.18 0.784     DDD 
SPIN1 1 9:91,083,440 A>G MS 0 1 
    
DDD 
USP14 1 18:203,143 C>T SG -- --     DDD  
M3 genes reported with non-synonymous de novo mutations (nsDNM) identified in  heterogeneous 
neurodevelopmental phenotypes. We detail the number and kind of nsDNM and for each single 
nucleotide variant, Sift and Polyphen2 scores were calculated using the Ensembl SNP Effect Predictor 
tool49. ASD, autism spectrum d isorder; ID, intellectual disability; EE, epilepsy; SCZ, schizophrenia; 
DDD, Deciphering Developmental Disorders; SV, splice variant; SG, stop gain; MS, missense. 
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METHODS 
 
Human surgical hippocampus gene expression data generation: Genome-wide gene 
expression data were generated from 122 snap frozen whole hippocampus samples surgically 
removed from patients who had undergone en bloc amygdalahippocampectomy for mesial 
temporal lobe epilepsy (MTLE) as previously described50. Informed consent was obtained 
from all patients and the study was approved by statutory Ethics Committees and Institutional 
Review Boards. Clinical data recorded for each patient included: date of birth, gender, 
handedness, age at epilepsy onset, laterality of TLE, operation date, age at operation, pre-
operative seizure frequency, antiepileptic drug therapy at the time of surgery and 
neuropathology. Genome wide gene expression was assayed as previously described50. 
Expression data were normalized by quantile normalization with background subtraction. 
Prior to network analysis, the data were filtered as follows: first, non-expressed probes were 
removed using the internal P values of detection provided by Illumina BeadArray Reader. 
Probes were retained if they passed 95% confidence threshold in at least 30% of the samples. 
Second, probes were removed if their sequences did not map uniquely to the reference 
genome or if the target regions contained at least one known SNP, as accessed by ReMOAT51. 
Third, the coefficient of variation (standard deviation/mean) in gene expression was used to 
remove the 5% of probes showing the lowest variation in gene expression in the TLE cohort. 
These filtering steps defined a final dataset of 11,837 probes, representing 9,616 protein 
coding unique genes (Ensembl version 72), which were then used for network analysis and as 
the “background” gene set for enrichment analyses. 
 
Gene co-expression network analysis of human surgical hippocampus samples: Before 
inferring gene co-expression networks, we used principal component (PC) analysis to 
calculate summary variables describing the variation in the microarray expression of the 
11,837 probes and estimate the potential effects of clinical covariates on global gene 
expression variability. The first three PCs explained the following fraction of variation in 
gene expression: PC1 - 25%, PC2 - 15% and PC3 - 8%, with other components explaining 
<5% of the variability in gene expression. We assessed the impact of clinical covariates age, 
gender, epilepsy severity, anti-epileptic drug (AED) load and hippocampal “pathology type” 
(i.e., Ammons Horn Sclerosis alone or in association with reactive astrogliosis and/or 
neuronal loss) on global gene expression by calculating univariate correlations between PC1-
PC3 and each clinical covariate. After Bonferroni correction for multiple testing, “pathology 
type” was the only covariate to show a significant effect on gene expression in epileptic 
hippocampus (P=1.1x10-4, R2=0.24 on PC1 of global gene expression). PC1 summarizes 25% 
of the global variation in gene expression and since “pathology type” explained only a limited 
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fraction of this variability (R2=0.24) this was considered the only relevant covariate. This is in 
keeping with our previous analyses where we showed no significant effects from clinical 
covariates (apart from epilepsy pathology as shown here)50. Gene expression levels were 
therefore adjusted to remove the effect of “pathology type” by fitting linear models on gene 
expression and accounting for pathology using the lm function in R. The residuals from the 
linear model were then used in the co-expression network analysis. 
 
Genes were then grouped into modules using weighted gene co-expression network analysis 
(WGCNA)14 on the set of 11,837 probes in 122 human hippocampus samples. WGCNA 
builds undirected co-expression networks where the nodes of the network correspond to genes 
and edges between genes are determined by the pairwise correlations between the genes’ 
expression levels. To avoid outlier bias, Tukey’s biweight method52 was used to compute 
robust pairwise correlations of gene expression. The strength of relationships between probes 
is defined as the adjacency matrix, which is calculated by applying a power function 
(connection strength = |correlation|β) on the biweight correlation matrix. The power function 
reduces the strength of weak correlations while preserving connection strength of highly 
correlated probes. Higher values of β increase this effect and increase specificity of gene 
interactions, while a lower β increases sensitivity. For the network analysis in the surgical 
hippocampus and for the comparative networks analyses in different datasets (see below), the 
beta was chosen to optimize the scale free property and the sparsity of connections between 
genes in each dataset. Then, the adjacency matrix is used to calculate the topological overlap 
matrix (TOM), which measures the number of neighbors that a pair of probes have in 
common, relative to the rest of the probes. Average hierarchical clustering was used to group 
genes based on the dissimilarity of gene connectivity, defined as 1 – TOM. The dynamic cut-
tree method53 was used to cut the dendrogram on a branch-by-branch basis to produce co-
expression clusters.  
 
Reproducibility of TLE hippocampal modules in control (non-diseased) human and 
mouse hippocampus samples: Several independent hippocampal gene-expression datasets 
were used to establish module reproducibility. To establish reproducibility of modules in non-
diseased human hippocampus we used human post-mortem hippocampus microarray 
expression data from 63 healthy post-mortem human brains publically available from Pritzker 
Neuropsychiatric Disorders Research Consortium 
(http://www.pritzkerneuropsych.org/?page_id=1196). To investigate module conservation 
across species, we generated mRNA-sequencing (RNA-seq) expression data from 100 healthy 
mouse hippocampi as follows: total RNA was isolated from snap frozen hippocampi from 
100 healthy (Crl:NMRI(Han)-FR) mice. Mouse hippocampus samples were ascertained 
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strictly in accordance with statutory ethical guidelines/regulations. cDNA and sample 
preparation for RNA sequencing followed manufacturer protocol (TruSeq RNA kit, Illumina). 
Samples were sequenced on an Illumina HiSeq 2000 sequencer as paired-end 75-nucleotide 
reads. Raw reads were mapped to the reference mouse genome (mm10) using TopHat54 
version 2.0.8. Read counts per gene were calculated for each sample using HTseq version 
0.5.3 (http://www-huber.embl.de/users/anders/HTSeq) and subsequently normalized across 
all the samples using trimmed mean of M-value (TMM) approach55. For each replication gene 
expression dataset we checked whether human surgical modules had higher connectivity in 
the replication datasets than expected by chance. For each replication gene expression dataset, 
the adjacency matrix was calculated using biweight correlations and the β value was chosen 
to optimize scale free property of the networks. The adjacency matrix was used to calculate 
topological overlap matrix (TOM) using WGCNA. For each of the 24 networks (M1-M24) 
detected in the 122 TLE subjects, empirical P values for the significance of the co-expression 
relationships were calculated by comparing the average topological overlap for network genes 
in the replication datasets (human or mouse) to the average connectivity of 10,000 randomly 
sampled networks56. The randomly sampled networks had the same size of the networks 
detected in the TLE patients (M1-M24). 
Module co-expression across brain regions: To determine whether co-expression of genes 
in modules M1 and M3 are preserved across topographically distinct cortical regions, we 
analysed genome-wide gene expression data from four brain regions (cerebellum, temporal 
cortex, occipital cortex, frontal cortex) using 102 post-mortem human brains from the UK 
Brain Expression Consortium (UKBEC) (GSE60862)57. Each brain region was treated as an 
independent dataset. Raw expression profiles from the Affymetrix Human Exon 1.0 ST Array 
were processed to transcript-level expression with Affymetrix Power Tools (APT)                      
(http://www.affymetrix.com/partners_programs/programs/developer/tools/powertools.affx) 
using probe logarithmic intensity error (plier) normalisation58 with probe GC-content 
correction. Only the most reliable ‘core’ set of probes was used to generate transcript level 
expression profiles as defined by Affymetrix. Exons were considered as ‘expressed’ if more 
than 50% of the samples had detection above background P-values below 0.01, as calculated 
using APT. Gene-level expression was obtained by taking the median of the expression 
values of multiple exons mapping to the same gene. Expression profiles from each brain 
region were analysed as independent datasets and were processed separately. This means that 
some genes were considered as ‘expressed’ in some brain regions and not in others (number 
of unique Ensembl genes expressed per brain region as follows: Frontal Cortex 14,800, 
Temporal Cortex 14,777, Cerebellum 15,162, Occipital Cortex 14,815).  
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Gene expression profiles were corrected for measured clinical covariates – age, gender, post-
mortem interval, cause of death and the source of the samples (i.e., brain-bank ID). The data 
were also adjusted for any potential batch effects using probabilistic estimation of expression 
residuals (PEER)59. PEER uses factor analysis to infer hidden determinants that explain large 
proportions of variability in the data. This approach allows expression data to be corrected for 
the effects of measured covariates such as age and sex as well as other potential sources of 
bias such as batch effects, environmental influences, sample history and other unknown 
factors59. Comparative network analysis was undertaken as previously (above) using the 
default network dissimilarity measure in WGCNA based on the topological overlap matrix 
(TOM)14, and empirical P values for the reproducibility of networks calculated by comparing 
the average topological overlap for module genes to the average connectivity of 10,000 
randomly sampled networks. 
 
Spatiotemporal analysis of module expression: To determine the spatiotemporal expression 
dynamics of modules, we used quantile normalized gene level expression values (log2 
transformed) from GSE6086229. This transcriptome data was generated using Affymetrix 
Human Exon 1.0 ST array analysis of 16 brain regions comprising the cerebellar cortex, 
mediodorsal nucleus of the thalamus, striatum, amygdala, hippocampus, and 11 areas of the 
neocortex. The data were generated from 1,263 samples collected from 53 clinically 
unremarkable postmortem human brains, spanning embryonic development to late adulthood 
(from 10 weeks of post-conception to 82 years of age, which corresponded to periods 3–15, 
as previously designated)29. The log2-transformed gene expression data follows a bimodal 
distribution contributed by low (likely non functional) and high expressed genes60. We used 
the expectation maximization (EM) algorithm to model gene expression levels as mixture of 
normal distributions and identify the underlying distributions of low and high expressed genes. 
Only the genes, with mean of log2-transformed expression values over the 95% percentile of 
distribution of low-expressed genes (here > 5.61) were considered for further analysis 
(n=8,704). The EM algorithm was implemented using normalMixEM function from the 
mixtools R package. Spatio-temporal dynamics of co-expression modules M1 and M3 across 
16 brain regions and 13 developmental time points were illustrated as a heatmap (Figure 1d, 
main text), as previously described28. Module expression for each region and developmental 
time point was calculated by averaging the scaled expression across all genes in a module. 
The resultant heatmap graphs illustrate the changes in expression of genes of a co-expression 
module across brain development and cortical regions.  
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Functional enrichment analysis of networks: Co-expression modules were functionally 
annotated using WebGestalt30 with terms of Kyoto Encyclopedia of Genes and Genomes 
(KEGG)61, “Pathway Commons” and Gene Ontology (GO)62 terms. For each dataset, we 
conservatively used all hippocampus-expressed genes (including those that contributed to the 
individual co-expression modules) as the background in the functional enrichment analyses. 
For each gene set (module), the ratio of enrichment (r), r = k /ke is calculated as the number of 
genes in the module (k) over the expected value (ke) of genes in the reference as determined 
by WebGestalt30. 
 
Assessment of overrepresentation of synaptic genes in modules: Enrichment of 
postsynaptic genes in the modules was assessed by hypergeometric test (two-tail). The ARC 
or NMDAR gene list was sourced from a published study (80 genes – see supplementary 
table 9 in publication17). The postsynaptic density (PSD) gene list used was the consensus 
human PSD genes (supplementary table 2 in publication22) that had an Ensembl gene ID (745 
out of 748 genes). PSD and ARC/NMDAR genes were tested for overrepresentation in the 
modules using the list of brain expressed genes (n=9,616 genes).  
 
Genome-wide association study (GWAS) of cognitive phenotypes: We undertook analysis 
of four cognitive phenotypes in two independent community-based cohorts. Our Discovery 
cohort consisted of participants in “Generation Scotland: Scottish Family Health Study” 
(GS:SFHS)24 and our Replication cohort consisted of participants in the Lothian Birth Cohort 
1936 (LBC1936)25. The same four cognitive phenotypes were analyzed in both LBC1936 and 
GS:SFHS; these were general fluid cognitive ability, crystallized ability, memory (delayed 
recall) and information processing speed. For LBC1936, the general fluid factor was derived 
using the six non-verbal tests from the Wechsler Adult Intelligence scale IIIuk63: Matrix 
reasoning, Digit span backward, Symbol search, Digit symbol coding, Block design, and 
Letter-number Sequencing. The raw scores from each of these tests were used in a principal 
components (PC) analysis where the first unrotated PC was extracted using regression. Next, 
each participant’s score on this PC was linearly regressed against age, sex and the first four 
multidimensional scaling components (to control for population stratification) used as 
predictor variables. The residuals from this model were then used in subsequent analyses. For 
crystallized ability, the National Adult Reading Test (NART)64 was used. For memory and 
information processing speed, the Delayed memory section from the logical memory section 
and the Digit symbol section of the WAIS-IIIUK63 were used, respectively. For each of these 
single tests the effect of age, sex, and population stratification was controlled for using 
regression approaches (as described above), and the standardized residuals from the 
regression model were used in the downstream analyses.  
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In GS:SFHS: the general cognitive ability the raw scores from the Digit Symbol Substitution 
Task63, the delayed and immediate sections of the Logical Memory Test65, Verbal Fluency66, 
and the Mill Hill Vocabulary Scale67, were subjected to a principal components analysis 
where the first unrotated PC was extracted using regression. This PC was then used as the 
dependent variable in a linear regression model with age, sex and the first six principal 
components (to control for population stratification) used as predictor variables. The residuals 
from this model were then extracted and carried forward for enrichment analysis. Whilst 
different tests were used in the construction of the general factor in GS:SFHS and in 
LBC1936, correlations between general factors constructed from different test batteries is 
high68,69. As with LBC1936, for crystallized ability, memory, and information processing 
speed only a single test was used. For crystallized ability this was the Mill Hill Vocabulary 
Scale67, for memory the delayed section of the Logical Memory Test65, and for information 
processing speed the Digit Symbol Substitution Task63 was used. As for general cognitive 
ability, the effects of age, sex and population stratification were controlled for using 
regression. Using these cognitive phenotypes we then undertook a standard GWAS of 
cognitive phenotypes in GS:SFHS and LBC1936 separately, as follows.  
 
GWAS in GS:SFHS: GS:SFHS was composed of families recruited from the population of 
Scotland between 2006 and 2011. A total of 7,953 unrelated individuals aged between 35 – 
65 years were recruited from Glasgow, Tayside, Ayrshire, Arran, and the North-East of 
Scotland. 95% of subjects were contacted through their general practitioner (GP) with the 
remaining 5% contacted through word of mouth. These individuals family members were also 
recruited yielding a sample size of 24,084 with an age range of 18-100 years of age. A full 
description of the GS:SFHS is provided by Smith et al. , 200670 and Smith et al. , 201224. DNA 
from blood (or saliva from clinical and postal participants) was extracted following informed 
consent from 10,000 Caucasian participants who were born in the UK. DNA was processed 
and stored using the standard operating procedures at the Wellcome Trust Clinical Research 
Facility Genetics Core in Edinburgh71. Genotyping was undertaken on Illumina 
HumanOmniExpressExome-8 v1.0 DNA Analysis BeadChip. In order to ensure 
comparability between the LBC1936 cohort and GS:SFHS, the UCSC Batch Coordinate 
Conversion (liftOver) (https://genome.ucsc.edu/cgi-bin/hgLiftOver) tool was used to convert 
the hg 19 build of GS to hg 18. In order to control for the effect of shared environment 
subjects who were related to another participant were removed (estimated kinship >0.025) 
leaving a total of 6,816 unrelated participants. Following QC a total of 594,756 SNPs with a 
minor allele frequency (MAF) of >0.01 were included in the analysis. Cognitive phenotypes 
were derived as described above and the effects of age, sex and population stratification 
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controlled for as described previously. The standardized residuals were used for subsequent 
single-SNP GWAS which was performed using PLINK72. Single SNP P values of association 
to individual cognitive scores were then used in the GWAS enrichment analysis (see below).  
 
GWAS in LBC1936: The LBC1936 cohort consisted of 1,091 cognitively healthy individuals 
(548 men and 543 women) assessed on cognitive and medical traits at a mean age 69.6 years 
(SD = 0.8). Informed consent was obtained from all subjects. All subjects were of Caucasian 
descent and almost all lived independently in the Lothian region (Edinburgh city and 
surrounding area) of Scotland. Genotyping using the Illumina 610-Quadv1 array was 
performed at the Wellcome Trust Clinical Research Facility, Edinburgh. Quality control 
measures were as follows: individuals were excluded from the study based on unresolved 
gender discrepancy, relatedness (so that no pair remained with estimated kinship >0.025), 
SNP call rate (≤ 0.95) and evidence of non-Caucasian descent. A total of 542,050 single 
nucleotide polymorphisms (SNPs) meeting the following conditions were included in the 
analysis: call rate ≥0.98, minor allele frequency ≥0.01 and Hardy–Weinberg equilibrium test 
with P≥0.001. After QC, we included 1,003 participants in the association analysis. 
Derivation of the cognitive phenotypes is described above, followed by correction for age, 
sex and population stratification. The standardized residuals were used for genotype-
phenotype analyses by PLINK72. Single SNP P values of association to individual cognitive 
scores were then used in the GWAS enrichment analysis (see below).  
 
GWAS-enrichment analysis: To test for enrichment of genetic association in a gene-set (i.e., 
co-expression module) we used VEGAS26 to generate a gene-based association statistic (P-
value) controlled for the number of SNPs in each gene and the LD between those SNPs. In all 
analyses gene-based P-values were calculated using VEGAS and the top 10% option with 
100,000 iterations and a gene window consisting of the transcriptional start and stop position 
of each gene. For both GS:SFHS and LBC1936 the genotype data from the GWAS 
participants was used to control for LD (rather than the default HapMap population) as this is 
expected to provide a more accurate estimate of the LD structure, which can be specific of the 
population cohort analyzed. For the other GWAS for which raw genotype data were not 
available (the Psychiatric Genomics Consortium (PGC) traits, International League Against 
Epilepsy (ILAE) Consortium on Complex Epilepsies - see Supplementary Table 9, and the 
non-cognitive control GWAS datasets of waist-hip ratio, fasting glucose homeostasis, glucose 
challenge homeostasis, systolic blood pressure and diastolic blood pressure - see 
Supplementary Table 6) the default HapMap population was used to control for LD in the 
VEGAS analysis. The GWAS-enrichment statistic was calculated for a given module from 
the gene-based association P-values (from VEGAS) using the Z-test based bootstrapping 
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method73 (one-sided) where, for each network, 100,000 random gene sets of same size as the 
network were sampled from the list of all hippocampus expressed genes (n=9,616). P-values 
of enrichment for the Discovery cohort were considered significant if they passed false 
discovery rate correction for the number of modules tested, as indicated in each case. 
 
Using RVIS to assess the genic intolerance properties of specific modules. The extent of 
human-specific genic constraint was estimated for each of the 24 co-expression modules by 
using the genic protein-coding intolerance scores (RVIS)34. RVIS was only calculated for 
protein-coding genes that had at least one protein-coding transcript that was publically 
approved among the CCDS Release 9 database74, and that had ≥70% of their CCDS real-
estate adequately covered among the population database adopted in their original manuscript 
(ESP6500)34. This resulted in scores for 16,956 assessable CCDS release 9 genes, thus all 
RVIS comparisons are restricted to these 16,956 “assessable” genes. We found that 89.4% of 
the genes across all modules had an assessable RVIS score. To determine whether a module 
was enriched for genes that are relatively more intolerant to functional variation than the rest 
of the genes expressed in the human hippocampus (n=8,414 with CCDS), a two-tail Mann-
Whitney U test was used to compare the distribution of genic RVIS scores for each module to 
the distribution from the rest of the hippocampus-expressed protein-coding genes outside of 
the module (module-level RVIS results are reported in full in Supplementary Table 7). 
 
Assessing the relationship between co-expression modules and neurodevelopmental 
disorder ascertained rare de novo mutations: We collated published de novo mutation 
(DNM) datasets to determine whether any relationships exists between co-expression 
modules and the DNMs reported in neurodevelopmental trio whole-exome sequencing (WES) 
studies. Collectively, the neurodevelopmental disease cohort consisted of 5,738 non-
overlapping published parent-offspring trios across four disease phenotypes; autism spectrum 
disorder (ASD, n=4,186)44,75, schizophrenia (SCZ, n=1,004)21,76,43,42,77 intellectual disability 
(ID, n=192)41,78,79 and epileptic encephalopathy (EE, n=356)80,81. Additionally, we considered 
DNMs from an independent cohort of 1,133 trios with severe, previously undiagnosed 
developmental disease from the Deciphering Developmental Disorders (DDD) study36,37. For 
controls, we used 1,891 non-neurological control samples from seven published 
studies38,39,40,41,42,43,44. 
 
Each module’s genetic relationship to disease was tested using two approaches. First, we 
compared rates of DNMs in each module compared to random expectation based on the 
collective consensus coding sequence (CCDS) of module genes. In the absence of individual 
trio data across the different studies, we cannot determine the effectively sequenced real-
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estate for each gene so we took the conservative route by assuming each gene has 100% of its 
CDDS sequence covered across all trios, appreciating that some genes will not have been 
adequately covered due to reasons such as capture kit specifications or low coverage. Thus, 
the expected numbers of DNM for each gene set is calculated based on the length of CCDS 
sequence of genes in the set and the overall frequency of DNM in all CCDS genes. Then to 
estimate the enrichment we used the ratio between the observed number of DNM in the gene 
set and the expected number based on this length model using binomial exact test (BET, two-
tail). Secondly, to accommodate for sequence context factors such as the inherent mutability 
of genes in a module, we adopted a Fisher's exact test (FET, two-tail) to empirically compare 
the rates of DNMs overlapping the CCDS real estate of a module in case- and control cohorts. 
This approach is also able to capture modules comprised of genes that are preferentially 
depleted of DNMs in healthy control cohorts. For each module, we report single nucleotide 
variant (SNV) DNM enrichments by both approaches and by considering three main classes 
of DNM: (a) predicted deleterious DNM (pdDNM) consisting of loss-of-function (i.e., 
nonsense and splice-site mutations) plus with missense mutations with SIFT82 score ≤0.05 
and Polyphen283 score ≥0.5, (b) non-synonymous DNM (nsDNM) consisting of all missense, 
nonsense and splice-site SNV mutations and (c) synonymous DNM (as a negative control). 
Polyphen2 and SIFT scores were obtained using the Variant Effect Predictor Ensembl tool49. 
For completeness, we also calculated enrichments considering only loss-of-function 
(nonsense and splice-site) mutations but because DNMs in this class were relatively 
infrequent, when considered alone, we expect limited power to detect significant enrichments. 
Finally, to establish specificity of the module-level results, we calculated enrichment of DNM 
for each class of DNM among all genes significantly expressed in the human hippocampus 
(termed “Background” genes, n=9,616) taking the conservative route of including among this 
set of genes all genes contributing to the individual modules.   
A supplementary methods checklist is available. 
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